scispace - formally typeset
Open AccessJournal ArticleDOI

Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions.

TLDR
Human renal tissues from patients with DN or IgA nephropathy were examined with specific antibodies to characterize most, if not all, carbonyl modifications of proteins by autoxidation products of carbohydrates, lipids, and amino acids, and these data suggest a broad derangement in nonenzymatic biochemistry in diabetic glomerular lesions.
Abstract
. Advanced glycation end products (AGE) include a variety of protein adducts whose accumulation has been implicated in tissue damage associated with diabetic nephropathy (DN). It was recently demonstrated that among AGE, glycoxidation products, whose formation is closely linked to oxidation, such as carboxymethyllysine (CML) and pentosidine, accumulate in expanded mesangial matrix and nodular lesions in DN, in colocalization with malondialdehyde-lysine (MDA-lysine), a lipoxidation product, whereas pyrraline, another AGE structure whose deposition is rather independent from oxidative stress, was not found within diabetic glomeruli. Because CML, pentosidine, and MDA-lysine are all formed under oxidative stress by carbonyl amine chemistry between protein amino group and carbonyl compounds, their colocalization suggests a local oxidative stress and increased protein carbonyl modification in diabetic glomerular lesions. To address this hypothesis, human renal tissues from patients with DN or IgA nephropathy were examined with specific antibodies to characterize most, if not all, carbonyl modifications of proteins by autoxidation products of carbohydrates, lipids, and amino acids: CML (derived from carbohydrates, lipids, and amino acid), pentosidine (derived from carbohydrates), MDA-lysine (derived from lipids), 4-hydroxynonenal-protein adduct (derived from lipids), and acrolein-protein adduct (derived from lipids and amino acid). All of the protein adducts were identified in expanded mesangial matrix and nodular lesions in DN. In IgA nephropathy, another primary glomerular disease leading to end-stage renal failure, despite positive staining for MDA-lysine and 4-hydroxynonenal-protein adduct in the expanded mesangial area, CML, pentosidine, and acrolein-protein adduct immunoreactivities were only faint in glomeruli. These data suggest a broad derangement in nonenzymatic biochemistry in diabetic glomerular lesions, and implicate an increased local oxidative stress and carbonyl modification of proteins in diabetic glomerular tissue damage (“carbonyl stress”).

read more

Citations
More filters
Journal ArticleDOI

Advanced glycation end-products: a review.

TL;DR: The chemistry of advanced glycated end-product formation and their patho-biochemistry particularly in relation to the diabetic microvascular complications of retinopathy, neuropathy and nephropathy as well as their role in the accelerated vasculopathy observed in diabetes are discussed.
Journal ArticleDOI

Advanced glycation end products: sparking the development of diabetic vascular injury.

TL;DR: Because of the emerging evidence about the adverse effects of AGEs on the vasculature of patients with diabetes, a number of different therapies to inhibit A GEs are under investigation.
Journal ArticleDOI

4-Hydroxy-2-nonenal: a product and mediator of oxidative stress.

TL;DR: A comprehensive summary of 4-Hydroxy-2-nonenal, as the product and mediator or oxidative stress is provided.
Journal ArticleDOI

The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society.

TL;DR: This review summarises the results and discussions of an UNESCO‐MCBN supported symposium on oxidative stress and its role in the onset and progression of diabetes and suggests a role for ROI in the development of insulin resistance.
Journal ArticleDOI

The pathogenesis of diabetic nephropathy.

TL;DR: A summary of the latest published data dealing with mechanisms contributing to diabetic nephropathy, including alterations in various cytokines and their interaction with products of advanced glycation and oxidant stress is provided.
References
More filters
Journal ArticleDOI

Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes.

TL;DR: This review provides a comprehensive summary on the chemical properties of 4-hydroxyalkenals and malonaldehyde, the mechanisms of their formation and their occurrence in biological systems and methods for their determination, as well as the many types of biological activities described so far.
Journal ArticleDOI

Role of Oxidative Stress in Development of Complications in Diabetes

TL;DR: Structural characterization of the cross-links and other products accumulating in collagen in diabetes is needed to gain a better understanding of the relationship between oxidative stress and the development of complications in diabetes.
Journal ArticleDOI

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

TL;DR: This seminar reviews recent studies suggesting that the central pathologic features of diabetic complications are caused by the hyperglycemia-accelerated formation of nonenzymatic advanced gly...
Journal ArticleDOI

Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins.

TL;DR: RAGE is a new member of the immunoglobulin superfamily of cell surface molecules and shares significant homology with MUC 18, NCAM, and the cytoplasmic domain of CD20 and could potentially mediate cellular effects of this class of glycosylated proteins.
Journal ArticleDOI

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking

TL;DR: The identification of aminoguanidine as an inhibitor of advanced nonenzymatic glycosylation product formation makes possible precise experimental definition of the pathogenetic significance of this process and suggests a potential clinical role for aminogsuanidine in the future treatment of chronic diabetic complications.
Related Papers (5)